{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-018776","form_type":"8-K","ticker":"LGVN","cik":"0001721484","company_name":"Longeveron Inc.","filed_at":"2025-02-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.586491+00:00","generated_at":"2026-05-25T23:41:40.348280+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Longeveron FY2024 revenue up 237% to $2.4M; net loss narrows 25% to $16.0M","bullets":["Total revenue $2.4M (FY2023: $0.7M) driven by Bahamas Registry Trial and new manufacturing contract.","Net loss $16.0M vs $21.4M in 2023; cash & equivalents $19.2M, runway into Q4 2025.","Pivotal ELPIS II HLHS trial >90% enrolled; enrollment expected to complete Q2 2025.","BLA submission for Lomecel-B (laromestrocel) in HLHS anticipated in 2026 if trial successful.","FDA meeting for mild Alzheimer’s disease pathway expected late Q1 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-018776","json":"https://secwatch.observer/filing/0001213900-25-018776.json","markdown":"https://secwatch.observer/filing/0001213900-25-018776.md","text":"https://secwatch.observer/filing/0001213900-25-018776.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1721484/000121390025018776/0001213900-25-018776-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1721484/000121390025018776/ea0232284-8k_longeveron.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-25T23:41:40.348280+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}